Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

"We are excited to collaborate with PHC to unlock new possibilities in cell culture,” explained Michael May, President and ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune disorders ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

Zilovertamab vedotin is currently being evaluated in the Phase 2/3 waveLINE-003 dose confirmation and expansion trial (NCT05139017 ... About diffuse large B-cell lymphoma Lymphoma is cancer ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues ...

This new distribution center underscores our commitment to delivering high-quality functional antibodies to researchers ...